ArticleCancer & metabolism2026
Fos-induced osteosarcoma growth causes a cachexia-like phenotype in mice and correlates with high Fgf21 serum levels.
Article in Cancer & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe dimeric AP-1 transcription factor has been described as a regulator of bone metabolism, but also of adipocyte biology. More specifically, its family members adopt specific functions in the regulation of adipocyte differentiation and adipose tissue hypoxia, but also in controlling lipolysis, energy expenditure and insulin sensitivity.
methodsIn this study, we analyzed the role of the AP-1 family member Fos, whose ubiquitous over-expression in transgenic mice has been described to cause osteosarcoma formation, on adipose tissue, glucose and lipid metabolism. More specifically, we analyzed the metabolic phenotype of the respective mouse model by histological analyses, monitoring gene expression, determination of serum parameters and ex vivo adipogenesis assays.
resultsWe show that FosTg mice additionally display an age-dependent loss of white adipose tissue, which is associated with reduced adipocyte size. Quantitative real-time PCR analyses of white adipose tissue as well as in vitro studies using adipocyte-derived stromal cells excluded a cell-autonomous defect in adipocyte differentiation. However, FosTg mice displayed low circulating glucose levels along with increased glucose tolerance and insulin sensitivity. By proteomic analysis we identified elevated serum levels of fibroblast growth factor 21 (Fgf21) in FosTg mice which could explain the observed reduced hepatic lipogenesis and white adipose tissue mass. Most importantly, we demonstrated that this metabolic phenotype is dependent on osteosarcoma formation by crossing the FosTg mice with mice deficient for Rsk2, a kinase necessary for tumor growth. Moreover, we could show a direct correlation between tumor burden and Fgf21 serum levels in our mouse model.
conclusionIn summary, our data identify Fgf21 as a potential regulator of glucose and lipid metabolism in Fos transgenic osteosarcoma-bearing mice, thereby supporting its essential function in the regulation of the metabolic phenotype associated with cancer cachexia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.